Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health (GH) is a leader in precision oncology, pioneering non-invasive liquid biopsy tests for cancer detection and monitoring. This dedicated news hub provides investors and healthcare professionals with timely updates on the company's financial performance, clinical advancements, and strategic initiatives.
Access authoritative coverage of earnings reports, regulatory milestones, and technology innovations shaping cancer diagnostics. Our curated collection includes press releases on clinical trial results, partnership announcements, and peer-reviewed research developments directly from Guardant Health's communications.
Key updates cover FDA clearances for diagnostic assays, global commercialization efforts, and data partnerships advancing precision medicine. Stay informed about developments in molecular residual disease detection, expanded test indications, and reimbursement progress affecting healthcare adoption.
Bookmark this page for consolidated access to verified information about liquid biopsy advancements and GH's role in transforming cancer care through genomic insights. Check regularly for objective reporting on developments impacting both clinical practice and investment considerations.
Guardant Health's Guardant Reveal, a blood-only liquid biopsy, is proven to detect minimal residual disease (MRD) in early-stage colorectal cancer (CRC) patients. In a study from Massachusetts General Hospital, Guardant Reveal demonstrated an industry-leading test sensitivity of 91% by integrating cancer-specific epigenomic signatures and genomic alterations, compared to 40%-50% in traditional tissue-dependent tests. This innovative approach may allow for better prognosis and tailored therapies without the need for tumor tissue.
Guardant Health (Nasdaq: GH), a precision oncology leader, will participate in the BofA Securities 2021 Healthcare Conference. The management team is set to engage in a fireside chat on May 12 at 2:00 p.m. PT / 5:00 p.m. ET. Interested parties can access the live and archived webcast via the company’s website.
Guardant Health focuses on revolutionizing cancer care through proprietary blood tests and advanced analytics. Their innovative tests aid in early detection and treatment of cancer, aiming to improve patient outcomes while reducing healthcare costs.
Guardant Health announces a collaboration with Daiichi Sankyo to seek regulatory approval for the Guardant360 CDx blood test as a companion diagnostic for Enhertu, targeting HER2 mutations in patients with advanced non-small cell lung cancer (NSCLC). This partnership aims to address unmet medical needs, enhancing patient outcomes with personalized medicine. The Guardant360 CDx test, already FDA-approved, offers comprehensive genomic profiling, crucial for guiding treatment decisions across solid tumors.
Guardant Health, Inc. (Nasdaq: GH) will announce its financial results for Q1 2021 on May 6, 2021, after market close. A conference call will follow at 1:30 p.m. PT/4:30 p.m. ET. The audio of the event will be accessible via the company's website and archived for later viewing. As a leader in precision oncology, Guardant Health uses proprietary blood tests to enhance cancer care and outcomes.
Guardant Health (Nasdaq: GH) presents significant findings at the AACR Virtual Annual Meeting, showcasing the effectiveness of its blood tests in precision oncology. Key data support the utility of Guardant360®, Guardant360 CDx, and GuardantOMNI™ in detecting actionable mutations and informing treatment pathways for cancer patients. The Guardant360 CDx has been validated for use with Amgen’s KRAS G12C inhibitor, sotorasib. Notably, the tests demonstrate high concordance with tissue biopsies, enhancing access to critical diagnostics. These advancements aim to improve treatment outcomes, particularly as healthcare recovers from the pandemic.
Guardant Health (Nasdaq: GH) has received approval from the New York State Department of Health for its Guardant Reveal™ liquid biopsy test, designed for detecting and monitoring minimal residual disease (MRD) in early-stage cancer patients. It is the first blood-only test with a 7-day turnaround to assess residual disease status without tissue biopsies. The test focuses initially on early-stage colorectal cancer and demonstrates an industry-leading sensitivity of 91% for detecting circulating tumor DNA (ctDNA). This innovation aims to improve patient management by identifying those who may benefit from adjuvant therapy.
Guardant Health (Nasdaq: GH) has received Advanced Diagnostic Laboratory Test (ADLT) status approval from CMS for its Guardant360 CDx test, the first FDA-approved liquid biopsy for tumor mutation profiling across all solid cancers. This ADLT status indicates that the test meets criteria for innovative products. Effective from January 1, 2022, Medicare will reimburse the test at $5,000 during a nine-month data collection period. This milestone is expected to facilitate broader payer coverage and enhance patient access to comprehensive genomic profiling, improving treatment options for advanced cancer patients.
A study published in JCO Precision Oncology demonstrates that the Guardant360® liquid biopsy test effectively indicates treatment response in patients with metastatic non-small cell lung cancer (mNSCLC) undergoing pembrolizumab-based therapy. In a study involving 51 patients, molecular responders experienced significantly improved progression-free survival (14.1 months) and overall survival (22.1 months) versus non-responders. Guardant Health's test analyzes DNA from blood samples to guide treatment decisions, addressing the need for early indications of therapeutic efficacy.
Guardant Health (Nasdaq: GH) is expanding its Clear Your View campaign to raise awareness for complete biomarker testing in newly diagnosed advanced colorectal cancer (CRC) patients. Despite guidelines recommending testing for six biomarkers, over 60% of patients do not receive complete testing, risking suboptimal therapy. The initiative encourages oncologists to “stop, test, and wait” for testing results to increase treatment efficacy. The campaign is supported by various patient advocacy groups and emphasizes the importance of personalized treatment to improve survival rates.
Guardant Health (Nasdaq: GH) has achieved CE-marking for the Guardant360® CDx test, which profiles tumor mutations in patients with any solid malignant neoplasm. This test is also approved as a companion diagnostic for non-small cell lung cancer patients with EGFR alterations, indicating suitability for Tagrisso® (osimertinib) treatment. CE-marking enhances global accessibility of Guardant360 CDx, crucial for guiding personalized cancer treatments based on comprehensive genomic profiling. The test complements Guardant Health's mission to advance precision oncology.
FAQ
What is the current stock price of Guardant Health (GH)?
What is the market cap of Guardant Health (GH)?
